Showing 1,681 - 1,700 results of 32,095 for search '(( e point decrease ) OR ( 50 ((((ns decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 0.90s Refine Results
  1. 1681
  2. 1682
  3. 1683
  4. 1684

    Effect of substrate binding on hNaa50p dynamics. by Cédric Grauffel (109194)

    Published 2012
    “…C: Map of the differences of correlation between simulations of hNaa50p-MLG and hNaa50p-apo. Red dots indicate an increase in correlation, while blue dots indicate a decrease. …”
  5. 1685
  6. 1686
  7. 1687

    Decreased expression of genes related to cholesterol biosynthesis and lipogenesis in PCA. by Sreejith P. Panicker (159572)

    Published 2012
    “…<i>EBP</i> expression was significantly decreased in the PCA subtypes TF, FFA and CCCA but not in DC, FD or LPP. …”
  8. 1688

    IC<sub>50</sub> is distinct for diclofenac, ibuprofen, and ASA. by Verena Leidgens (815986)

    Published 2015
    “…The assays showed a significant linear concentration-dependent decrease of cell viability, which significantly differed between (A) ibuprofen (IC<sub>50</sub>, 1 mM) and (B) diclofenac (IC<sub>50</sub>, 0.1 mM). …”
  9. 1689
  10. 1690

    Myosin phosphatase and RhoA-activated kinase modulate neurotransmitter release by regulating SNAP-25 of SNARE complex by Dániel Horváth (4015034)

    Published 2017
    “…Inhibition of PP1 with tautomycetin increased, whereas inhibition of ROK by H1152, decreased the phosphorylation of SNAP-25 at Thr138 in B50 cells, in cortical synaptosomes, and in brain slices. …”
  11. 1691

    PowerPoint Slides for: Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease by Martin E.R. (3859435)

    Published 2017
    “…<b><i>Methods:</i></b> A phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial (NCT01381094) was undertaken in adults with anemia secondary to CKD stage 3 or 4. …”
  12. 1692
  13. 1693
  14. 1694
  15. 1695
  16. 1696
  17. 1697
  18. 1698
  19. 1699
  20. 1700